Investor Relations

<< Back

Press Release

October 22, 2020 at 4:05 PM EDT

Anika to Issue Third Quarter 2020 Financial Results and Business Highlights on Wednesday, November 4, 2020

BEDFORD, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, today announced that the Company plans to issue its third quarter 2020 financial results after the close of the market on Wednesday, November 4, 2020 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

The conference call can be accessed by dialing 1-855-327-6837 (toll-free domestic) or 1-631-891-4304 (international) and providing the conference ID number 10011177. A live audio webcast will be available in the "Investor Relations" section of Anika's website, www.anika.com. An accompanying slide presentation also can be accessed via the Anika website. The call will be archived and accessible on the same website shortly after its conclusion.

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. We partner with physicians to understand what they need most to treat their patients and we develop minimally invasive products that restore active living for people around the world. We are committed to leading in high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies. For more information, please visit www.anika.com.

For Investor Inquiries:
Anika Therapeutics, Inc.
Kristen Galfetti, 781-457-9000
Executive Director, Investor Relations
investorrelations@anika.com

For Media Inquiries:
W2O Group
Rachel Girard, 617-379-6760
rgirard@w2ogroup.com


anika_new_logo_highres_360x133 (002) (1).png

Source: Anika Therapeutics Inc.